APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: Prognostic relevance of APRIL for survival

Haematologica

Volumn 92, Issue 9, 2007, Pages 1284-1285

  Planelles, Lourdes ^a,e   Castillo Gutiérrez, Sonia ^b   Medema, Jan Paul ^c   Morales Luque, Antonio ^b   Merle Béral, Hélène ^d   Hahne, Michael ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b UNIVERSITY OF JAÉN   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

APRIL serum levels; LLC; Overall survival; Prognostic factor

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 36348943503     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10317     Document Type: Article

References (8)

1. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-46.
2. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004;6:399-408.
3. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100:2973-9.
4. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Steunou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2003; 103:679-88.
5. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, et al. Neutrophil-derived APPIL concentrated in tumor lesions by proteoglycans correlates with human B cell lymphoma aggressiveness. Blood 2007; 109: 331-8.
6. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-9.
7. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunol 2006;118:281-292.
8. Novak AJ, Grote DM, Ziesmer SC, Ziesmer SC, Witzig TE, Habermann TM, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24:983-7